Sarah Boyce, Avidity Biosciences

Avid­i­ty’s ear­ly-phase da­ta for rare mus­cle dis­ease drug spur reg­is­tra­tional plans

Avid­i­ty Bio­sciences’ an­ti­body oligonu­cleotide con­ju­gate has shown signs of ef­fi­ca­cy in an ear­ly-stage test in pa­tients with a rare mus­cle-wast­ing dis­ease.

Just last month, Leerink …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.